Dow, S&P 500, Nasdaq Futures Rise As Oil Cools, War Fears Ease: Why SMCI, PL, FDX, AXTI, SLS Are Trending After-Hours
U.S. stock futures rose late Thursday as oil prices cooled and war fears eased. SMCI shares fell 12% after legal charges, PL surged 15% on strong Q4 results, FDX rose 9% on earnings beat, AXTI hit a record high, and SLS edged higher on narrowed losses. Dow, S&P 500, and Nasdaq closed lower but recovered from steeper losses.
How this was made
The 30-second read
Why it matters
The mix of fresh enforcement action (SMCI) and strong earnings beats (PL, FDX) creates divergent trading opportunities across sectors.
Market read
While macro factors lifted futures, company‑specific catalysts drove notable after‑hours price moves, offering immediate trade ideas.
What to watch
PL's defense revenue may be cyclical; watch for future government contract pipelines before scaling positions.
Background
Futures rose as oil cooled and war‑risk concerns eased; market sentiment was bearish on major ETFs but turned positive on specific corporate news.
Ticker impact
Shares slumped 12% after‑hours as U.S. prosecutors charged three individuals in an alleged scheme to smuggle Nvidia‑powered servers to China, a fresh enforcement action.
Short‑term downside of 8‑12% as investors reassess exposure.
First‑report of a criminal investigation; market typically reacts sharply to export‑law violations.
Planet Labs jumped 15% in extended trading after reporting strong Q4 results with revenue up 41% YoY to $86.8 million, driven by defense and intelligence demand.
Potential 5‑8% rally in the next session as momentum builds.
First earnings release with better‑than‑expected numbers; market reaction already evident.
FedEx rose 9% after‑hours after beating Q3 estimates and raising its FY26 outlook, a fresh earnings beat.
Likely 4‑6% upside as investors price in higher future earnings.
First‑report earnings beat; market already responded positively.
AXT Inc. hit a record high after B. Riley highlighted a denial of an InP bottleneck at an industry conference, lifting sentiment despite supply‑chain concerns.
Potential 3‑5% rally as the narrative shifts.
Analyst note is a fresh catalyst; market reaction already visible.
Sellas Life Sciences edged higher after reporting a narrower full‑year loss and stronger cash, with its Phase 3 AML trial nearing final analysis.
Modest 2‑4% upside as investors re‑evaluate risk.
Incremental financial improvement; impact likely limited.
Market effects
Tech export‑control enforcement may pressure other AI‑hardware firms; strong defense demand benefits satellite and logistics sectors.
Middle‑East tension easing supports broader market risk appetite, aiding logistics and industrials.
Oil price moderation and geopolitical de‑escalation lift global equity sentiment, but sector‑specific news dominate individual stock moves.
Counterpoint
SMCI's drop could be over‑reacted if the investigation does not lead to material penalties; consider a short‑cover bounce.
Key entities
- Regulatory BodyU.S. Department of Justice
Prosecuted the alleged smuggling scheme involving SMCI.
- Research FirmB. Riley
Provided positive commentary on AXTI's supply‑chain outlook.
